Stockreport

U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology Inc  (PBYI) 
Last puma biotechnology inc earnings: 2/20 04:07 pm Check Earnings Report
US:NYSE Investor Relations: pumabiotechnology.com/ir.html
PDF Neratinib becomes the first anti-HER2 treatment to be FDA-approved as extended adjuvant therapy for early-stage HER2-positive breast cancer f [Read more]